Aldatu Biosciences

Executive Summary

Aldatu Biosciences is a Cambridge-based biotechnology company pioneering adaptive molecular diagnostics for infectious diseases through its proprietary PANDAA™ platform. Founded in 2014, the company addresses a critical challenge in PCR diagnostics: detecting pathogens that undergo rapid genetic variation, such as HIV, SARS-CoV-2, and viral hemorrhagic fevers. PANDAA enables targeted amplification of highly variable genomic regions without requiring assay redesign, allowing tests to remain effective against emerging variants. This technology positions Aldatu as a key player in pandemic preparedness and global health, particularly in low-resource settings where variant surveillance is limited. The company’s focus on pan-degenerate amplification offers significant advantages over traditional PCR methods, reducing the need for frequent test updates and improving diagnostic accuracy. Aldatu’s pipeline includes assays for HIV viral load monitoring and point-of-care SARS-CoV-2 detection. With increasing demand for variant-agnostic diagnostics, Aldatu is well-positioned to capture market share. However, as a private company with limited public funding data, its near-term trajectory depends on securing regulatory approvals and commercial partnerships. The executive summary reflects Aldatu’s innovative technology but acknowledges execution risks in a competitive diagnostics landscape.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance or CE marking for HIV viral load assay using PANDAA technology40% success
• Q2 2027Strategic partnership with a major diagnostics company for global distribution of SARS-CoV-2 variant detection test50% success
• Q3 2026Publication of clinical validation data for pan-hemorrhagic fever diagnostic panel60% success